1
|
Cerbone L, Delfanti S, Crivellari S, De Angelis AM, Mazzeo L, Proto C, Occhipinti M, Lo Russo G, Dellepiane C, Biello F, Alabiso I, Verderame F, Gauna R, De Simone I, Cuppone F, Petraglia S, Pasello G, Ceresoli GL, Garassino MC, Torri V, Grosso F. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund. TUMORI JOURNAL 2024; 110:168-173. [PMID: 38372045 DOI: 10.1177/03008916241229287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2024]
Abstract
BACKGROUND Pleural mesothelioma is a rare cancer with a dismal prognosis and few therapeutic options, especially in the pretreated setting. Immunotherapy with checkpoint inhibitors as single agents yielded interesting results in refractory pleural mesothelioma, achieving a response rate between 10-20%, median progression-free survival of 2-5 months and median overall survival of 7-13 months. PATIENTS AND METHODS A retrospective, multi-institutional study of pleural mesothelioma patients treated with nivolumab in second and further line was performed. The endpoints of the study are response rate, disease control rate, progression free survival and overall survival. RESULTS Sixty-five patients with pleural mesothelioma treated with nivolumab in second and further line were enrolled at seven Italian institutions. The response rate was 8%, disease control rate was 37%, median progression free survival was 5.7 months (95% CI: 2.9-9.0) and median overall survival was 11.1 (95% CI 6.2-19.9) months. A higher neutrophils and neutrophils to lymphocytes ratio at baseline were associated with worse prognosis. CONCLUSION Nivolumab as a single agent is fairly active in a cohort of unselected pretreated pleural mesothelioma patients. Further investigations on clinical and translational factors are needed to define which patient might benefit most from nivolumab treatment in pleural mesothelioma.
Collapse
Affiliation(s)
- Luigi Cerbone
- Mesothelioma Unit AO SS, Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | - Sara Delfanti
- Mesothelioma Unit AO SS, Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | - Stefania Crivellari
- Mesothelioma Unit AO SS, Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
- Projects, Investigation and Innovation Unit, Ospedale Michele e Pietro Ferrero, Verduno, Italy
| | | | - Laura Mazzeo
- Medical Oncology Department 1, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Milano, Italy
| | - Claudia Proto
- Medical Oncology Department 1, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Milano, Italy
| | - Mario Occhipinti
- Medical Oncology Department 1, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Milano, Italy
| | - Giuseppe Lo Russo
- Medical Oncology Department 1, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Milano, Italy
| | - Chiara Dellepiane
- Lung Cancer Unit, Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - Federica Biello
- Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - Irene Alabiso
- Oncology Unit 2, Presidio Ospedaliero S. Giovanni Bosco, Azienda Sanitaria Locale Città Di Torino, Torino, Italy
| | - Francesco Verderame
- Medical Oncology Unit, Azienda Ospedaliera Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy
| | - Roberta Gauna
- Oncology Unit, Ospedale Degli Infermi, Ponderano, Italy
| | - Irene De Simone
- Clinical Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Federica Cuppone
- Pre-Authorisation Department, Italian Medicines Agency, Rome, Italy
| | - Sandra Petraglia
- Pre-Authorisation Department, Italian Medicines Agency, Rome, Italy
| | - Giulia Pasello
- Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy 12Department of Surgery, Oncology and Gastroenterology, University of Padua, Italy
- Department of Surgery, Oncology and Gastroenterology, University of Padua, Italy
| | | | - Marina Chiara Garassino
- Department of Medicine, University of Chicago Comprehensive Cancer Center, University of Chicago, Illinois, USA
| | - Valter Torri
- Clinical Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Federica Grosso
- Mesothelioma Unit AO SS, Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| |
Collapse
|